United States-based CONTINUUS Pharmaceuticals Inc announced on Thursday that it has received a USD69.3m United States government contract to facilitate domestic production of three vital medicines intended to treat critically ill patients, including those with COVID-19.
The Department of Defense (DoD) awarded the contract in collaboration with the Department of Health and Human Services (HHS).
The contract will also allow construction of the country's first Good Manufacturing Practices (GMP)-certified facility for end-to-end, ICM-driven production of small-molecule drugs, including marketed products, generic medications and investigational therapies through all phases of clinical trials and a product's lifecycle. CONTINUUS Pharmaceuticals is also breaking ground for a new facility in Woburn, Massachusetts and aims to make the facility completely operational within two years.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic